Novo Nordisk and Sanofi get FDA approval for type 2 diabetes combo drugs
Novo Nordisk and Sanofi have both received approval from the US Food and Drug Association (FDA) for drugs which combine insulin with a GLP-1 receptor agonist drug.
Danish company Novo Nordisk’s drug is Xultophy 100/3.6, a once daily injection combining Tresiba insulin and the GLP-1 drug Victoza. French company Sanofi’s new drug is Soliqua 100/33 a combination of Lantus insulin and the GLP-1 drug Lyxumia.
Both drugs from these companies are designed to help people with type 2 diabetes manage their blood glucose levels in conjunction with diet and exercise.
Jakob Riis, executive vice president and head of North America Operations of Novo Nordisk said that “Novo Nordisk is committed to discovering and developing new medicines, like Xultophy 100/3.6, that may make a difference in the way some adults with type 2 diabetes manage their diabetes and achieve their treatment goals.
“Combining Tresiba and Victoza into a single injection will offer patients a new option that may help control their blood sugar. We look forward to making Xultophy100/3.6 available to adults with type 2 diabetes in the first half of 2017.”
The drug gained approval thanks to the positive outcomes in three Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes (DUAL) clinical trials. It was shown that adults with type 2 that were having trouble controlling blood glucose levels with liraglutide or basal insulin therapy could achieve better HbA1c levels by using Xultophy 100/3.6.
Novo Nordisk are planning to launch Xultophy 100/3.6 in the first half of 2017, and the company is looking to secure access for Xultophy 100/3.6 on health plans across the country.
Meanwhile, Elias Zerhouni, M.D., President of Global Research and Development at Sanofi stated of their drug: “Sanofi continues to be a pioneer in developing diabetes therapies and in bringing forward new treatment options for the approximately 50 percent of patients whose blood sugar levels remain uncontrolled on daily basal insulin.
“Soliqua 100/33 is an alternate new approach that can help adults living with type 2 diabetes uncontrolled on basal insulin or lixisenatide to reach their treatment goal.”
Sanofi plans to launch Soliqua in January 2017 to be available in retail pharmacies across the US.
Add A Comment
- TRENDING: https://t.co/kfthtJCBWh Become a forum member here: https://t.co/7AMbMTH2Tf https://t.co/bEMDUD6kT7
- "Mines slightly different in that he's half a tonne of horse! He's a bit boisterous, but he'll never nudge my... https://t.co/9M6qRWjNMX
- DKA is a short term complication of high blood glucose levels in people with diabetes. https://t.co/5nCTMfRNqA